Anemia is a condition of the blood characterized by too few red blood cells to support normal physiology.[1] Anemia (AmE) or anaemia (BrE), from the Greek (Ἀναιμία) meaning "without blood", refers to a quantitative or qualitative deficiency of red blood cells (RBCs) and/or hemoglobin. It is clinically manifested as pallor. Homeostasis dictates that red cell production and destruction are usually balanced in an organism. Anemias are caused by either excess red cell destruction, or underproduction of red cells, because of reduced intake, or ineffective absorption through the GI tract, of essential nutrients like iron. Reduction in the red blood cell content of blood can have a wide range of clinical consequences, from no noticeable symptoms for gradual-onset anemia, to cardiovascular collapse and death from rapid, profound reductions, such as seen in bleeding.
The classification of anemia is commonly based on the etiology, or on the microscopic morphology of the red blood cells. Sometimes the morphology can give clues as to the etiology of anemia, as in the microcytic anemia of iron deficiency.
Hemoglobin is the pigmented protein in blood that carries oxygen; reductions in blood hemoglobin concentrations in anemia can lead to decreased oxygen delivery to tissues.
The measurement of anemia has changed with available technology. The spun hematocrit was one of the earliest indicators of anemia. Later, the development of the flow cytometry, first deployed as the Coulter Counter, automated the measurement of red blood cell size, and colorimetric assays facilitated the measurement of hemoglobin.
While it is common to use one of the basic red blood cell parameters, usually hematocrit, as a preliminary indicator of anemia, even before going to more advanced tests, the hematocrit alone should not be used for a firm diagnosis. The hematocrit measures the percentage of blood cells with respect to total blood, so a low hematocrit may indicate inappropriate fluid balance rather than true anemia. Dehydration can artificially raise the hematocrit, but if the body responds with a surge of fluid replacement, it can be low. Confirmation of anemia is best done with the erythrocyte indices, which consider ratios among the three core measurements. Small red blood cells (i.e., low mean corpuscular volume — MCV) may indicate the bone marrow is rushing to resupply cells; the MCV will go low even before the reticulocyte or nucleated red cell count. This is termed microcytic anemia. Also to be examined is the mean corpuscular hemoglobin concentration (MCHC), which, if low, suggests not enough hemoglobin is being produced for the erythrocytes. A low MCHC is a microchromic anemia, which may coexist with microcytic anemia.
The "kinetic" approach to anemia yields what many argue is the most clinically relevant classification of anemia. This classification depends on evaluation of several hematological parameters, particularly the blood reticulocyte (one precursor of mature RBCs) count; the reticulocyte count is not a part of the basic complete blood count. [[Nucleated red cell]s, which may be reported in the CBC, precede reticulocytes in the maturation of red blood cells. This then yields the classification of defects by decreased RBC production versus increased RBC destruction and/or loss. Clinical signs of loss or destruction include abnormal peripheral blood smear with signs of hemolysis; elevated LDH suggesting cell destruction; or clinical signs of bleeding, such as guiaic-positive stool, radiographic findings, or frank bleeding.
In the morphological approach, anemia is classified by the size of red blood cells; this is either done automatically or on microscopic examination of a peripheral blood smear. The size is reflected in the mean corpuscular volume (MCV). If the cells are smaller than normal (under 80 fl), the anemia is said to be microcytic; if they are normal size (80-100 fl), normocytic; and if they are larger than normal (over 100 fl), the anemia is classified as macrocytic. This scheme quickly exposes some of the most common causes of anemia; for instance, a microcytic anemia is often the result of iron deficiency. In clinical workup, the MCV will be one of the most reliable pieces of information available; so even among clinicians who consider the "kinetic" approach more useful pragmatically, morphology will remain an important element of classification and diagnosis.
Other characteristics visible on the peripheral smear may provide valuable clues about a more specific diagnosis; for example, abnormal white blood cells may point to a cause in the bone marrow.
Microcytic anemia is primarily a result of hemoglobin synthesis failure/insufficiency, which could be caused by several etiologies:
A mnemonic commonly used to remember causes of microcytic anemia is TAILS: T - Thalassemia, A - Anemia of chronic disease, I - Iron deficiency anemia, L - Lead toxicity associated anemia, S - Sideroblastic anemia.
Normocytic anaemia is when the overall Hb levels are decreased, but the red blood cell size (MCV) remains normal. Causes include:
Macrocytic anemia can be further divided into "megaloblastic anemia" or "non-megaloblastic macrocytic anemia". The cause of megaloblastic anemia is primarily a failure of DNA synthesis with preserved RNA synthesis, which result in restricted cell division of the progenitor cells. The megaloblastic anemias often present with neutrophil hypersegmentation (6-10 lobes). The non-megaloblastic macrocytic anemias have different etiologies (i.e. there is unimpaired DNA synthesis,) which occur, for example in alcoholism.
The treatment for vitamin B12-deficient macrocytic and pernicious anemias was first devised by William Murphy who bled dogs to make them anemic and then fed them various substances to see what (if anything) would make them healthy again. He discovered that ingesting large amounts of liver seemed to cure the disease. George Minot and George Whipple then set about to chemically isolate the curative substance and ultimately were able to isolate the vitamin B12 from the liver. For this, all three shared the 1934 Nobel Prize in Medicine. Symptoms of vitamin B12 deficiency include having a smooth, red tongue. Minot, in one of the dramas of medicine, was one of the first patients saved by insulin therapy, for which the 1923 Nobel Prize in Medicine was awarded.
Here there are two types of anemia simultaneously, e.g., macrocytic hypochromic, due to hookworm infestation leading to deficiency of both iron and vitamin B12 or folic acid [1] or following a blood transfusion. One hint that this kind of anemia may exist is a wide RBC distribution width (RDW), which suggests a wider-than-normal range of sizes of red blood cells.
Myelodysplastic syndrome is a loosely-defined condition of ineffectual hematopoeisis by the bone marrow. The hallmark characteristics of myelodysplastic syndrome are:
Aplastic anemia is clinical syndrome characterized by a hypoplastic bone marrow in the setting of pancytopenia. The pathogenesis of aplastic anemia is damage to the pluripotent stem cell reserves of the bone marrow.
Patterns of aplastic anemia include:
Four mechanisms contribute to anemia in the context of inflammatory disease:
Several categories of chronic diseases can contribute to anemia.
The production of red blood cells in the bone marrow depends on stimulation of erythroid stem cells by the growth factor, erythropoietin. Erythropoietin is principally manufactured in the kidneys, and the liver to a lesser extent.
About half of patients with chronic kidney disease and an estimated glomerular filtration rate of 25-30 ml/min have a hematrocrit below 36%.[2]
Erythropoietin deficiency in renal disease leads to an anemia that is correctable with recombinant pharmacological erythropoietin. A pair of articles in the New England Journal of Medicine in November, 2006 drew attention to the concept that excessive correction of anemia in renal failure patients did not improve cardiovascular function[3], and could in fact be deleterious. Patients treated to a higher target hemoglobin showed an improved quality of life, but had excess mortality, compared with patients treated to a lower target hemoglobin.[4]
The anemia of chronic disease or anemia of chronic inflammatory disease consist of anemias caused by poor iron reutilization by the reticuloendothelial system and inappropriate cytokine production in the inflammatory state. Some commonly-cited causes of the anemia of chronic disease:
Congestive heart failure is a cited etiology of anemia.
The anemia of malignancy is multifactorial, and can stem directly from bleeding, bone marrow compartment replacement by malignant cells, hemolytic anemia, immunoglobulin deposition, chemotherapy, or immune-mediated pure red-cell aplasia
Hemoglobinopathies include sickle cell anemia, thalassemias, and other hemoglobinopathies
Other causes of hereditary anemia include Fanconi anemia
These anemias are characterized by increased reticulocytes.[7] The percentage of red blood cells that are reticulocytes are normally less than 3% (usually 1.0% to 1.5%).[7] Alternative indices are:
Absolute reticulocyte count, normal is 50,000 and 150,000 reticulocytes/mL:[7]
The absolute reticulocyte count can be corrected for the increased time of circulation of reticulocytes in the peripheral blood during anemia. The normal reticulocyte maturation time in the peripheral blood is 1 day, but extends to 2 days at a hematocrit 25 percent:[7]
Reticulocyte index:[7]
In autoimmune hemolytic anemia, reticulocytes can be 9% of red blood cells and 75% of patients will double their reticulocyte production index.[7]
The physical examination has some ability to detect anemia. In one study:[8]
Conjunctival pallor is helpful.[9]
Learning the examination may be improved by learning standardized colors.[10]
Treatment is directed as the specific cause of anemia. In addition, blood transfusion or erythropoiesis-stimulating agents may be used.
Clinical practice guidelines address thresholds for blood transfusions:[11]
Among patients receiving coronary artery bypass grafting, there may be no meaningful difference between transfusing to maintain a hemoglobin levels > 8 g/dL versus a hemoglobin levels > 9 g/dL.[12] However, hemoglobin levels < 8 g/dL may increase complications.[13]
Among patients in critical care units, there may not be a meaningful difference in outcomes between transfusing blood to maintain a hemoglobin > 7.0 g/dl versus a hemoglobin > 10.0 g/dl except among patients with acute coronary syndrome.[14]
Using erythropoiesis-stimulating agents in patients with cancer may increase embolism and thrombosis and mortality.[15]
Among patient in critical care units, a randomized controlled trial reported "epoetin alfa does not reduce the incidence of red-cell transfusion among critically ill patients, but it may reduce mortality in patients with trauma. Treatment with epoetin alfa is associated with an increase in the incidence of thrombotic events."[16]